Combined Identification of Novel Markers for Diagnosis and Prognostic of Classic Hodgkin Lymphoma

References

• Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132. doi:10.3322/caac.21438
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Ramchandren R, Domingo-Domenech E, Rueda A, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the Phase II CheckMate 205 STUDY. J Clin Oncol. 2019;37(23):1997–2007. doi:10.1200/JCO.19.00315
   PubMed Web of Science ®Google Scholar
• Ansell SM. Immunotherapy in Hodgkin lymphoma: the road ahead. Trends Immunol. 2019;40(5):380–386. doi:10.1016/j.it.2019.03.003
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–344. doi:10.1056/NEJMoa1708984
   PubMed Web of Science ®Google Scholar
• Nie J, Wang C, Liu Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol. 2019;37(17):1479–1489. doi:10.1200/JCO.18.02151
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Li H, Hong F, et al. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015;171(4):530–538. doi:10.1111/bjh.13634
   PubMed Web of Science ®Google Scholar
• Zaucha JM, Chauvie S, Zaucha R, Biggii A, Gallamini A. The role of PET/CT in the modern treatment of Hodgkin lymphoma. Cancer Treat Rev. 2019;77:44–56. doi:10.1016/j.ctrv.2019.06.002
   PubMed Web of Science ®Google Scholar
• Mottok A, Steidl C. Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood. 2018;131(15):1654–1665. doi:10.1182/blood-2017-09-772632
   PubMed Web of Science ®Google Scholar
• Wilson CL, Miller CJ. Simpleaffy: a BioConductor package for affymetrix quality control and data analysis. Bioinformatics. 2005;21(18):3683–3685. doi:10.1093/bioinformatics/bti605
   PubMed Web of Science ®Google Scholar
• Kauffmann A, Gentleman R, Huber W. arrayQualityMetrics–a bioconductor package for quality assessment of microarray data. Bioinformatics. 2009;25(3):415–416. doi:10.1093/bioinformatics/btn647
   PubMedGoogle Scholar
• Xu R, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16(11):1155–1161. doi:10.1038/nmat4997
   PubMed Web of Science ®Google Scholar
• Onwuka J, Li D, Liu Y, et al. A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility. BMC Cancer. 2020;20(1):692. doi:10.1186/s12885-020-07194-5
   PubMed Web of Science ®Google Scholar
• Han B, Bhowmick N, Qu Y, Chung S, Giuliano A, Cui X. FOXC1: an emerging marker and therapeutic target for cancer. Oncogene. 2017;36(28):3957–3963. doi:10.1038/onc.2017.48
   PubMed Web of Science ®Google Scholar
• Elian F, Yan E, Walter M. FOXC1, the new player in the cancer sandbox. Oncotarget. 2018;9(8):8165–8178. doi:10.18632/oncotarget.22742
   PubMedGoogle Scholar
• Nagel S, Meyer C, Kaufmann M, Drexler H, MacLeod R. Deregulated FOX genes in Hodgkin lymphoma. Genes Chromosomes Cancer. 2014;53(11):917–933. doi:10.1002/gcc.22204
   PubMed Web of Science ®Google Scholar
• Kawano Y, Ouchida R, Wang J, et al. A novel mechanism for the autonomous termination of pre-B cell receptor expression via induction of lysosome-associated protein transmembrane 5. Mol Cell Biol. 2012;32(21):4462–4471. doi:10.1128/MCB.00531-12
   PubMed Web of Science ®Google Scholar
• Kiang K, Zhang P, Li N, Zhu Z, Jin L, Leung G. Loss of cytoskeleton protein ADD3 promotes tumor growth and angiogenesis in glioblastoma multiforme. Cancer Lett. 2020;474:118–126. doi:10.1016/j.canlet.2020.01.007
   PubMed Web of Science ®Google Scholar
• Olsson L, Castor A, Behrendtz M, et al. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia. 2014;28(2):302–310. doi:10.1038/leu.2013.206
   PubMed Web of Science ®Google Scholar
• Song Y, Wu J, Chen X, et al. A single-arm, multicenter, Phase II Study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clin Cancer Res. 2019;25(24):7363–7369. doi:10.1158/1078-0432.CCR-19-1680
   PubMed Web of Science ®Google Scholar
• Liu X, Shan C, Song Y, Du J. Prognostic value of programmed cell death Ligand-1 expression in nasopharyngeal carcinoma: a meta-analysis of 1,315 patients. Front Oncol. 2019;9: p. 1111. doi:10.3389/fonc.2019.01111
   PubMed Web of Science ®Google Scholar
• Qiu L, Zheng H, Zhao X. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis. BMC Cancer. 2019;19(1):273. doi:10.1186/s12885-019-5466-y
   PubMed Web of Science ®Google Scholar
• Wu Z, Yang L, Shi L, et al. Prognostic impact of Adenosine Receptor 2 (A2aR) and programmed Cell Death Ligand 1 (PD-L1) expression in colorectal cancer. Biomed Res Int. 2019;2019:8014627. doi:10.1155/2019/8014627
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex Class II and programmed death Ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018;36(10):942–950. doi:10.1200/JCO.2017.77.3994
   PubMed Web of Science ®Google Scholar
• Hou Y, Li X, Li Q, et al. STAT1 facilitates oestrogen receptor alpha transcription and stimulates breast cancer cell proliferation. J Cell Mol Med. 2018;22(12):6077–6086. doi:10.1111/jcmm.13882
   PubMed Web of Science ®Google Scholar
• Goodman ML, Trinca GM, Walter KR, et al. Progesterone receptor attenuates STAT1-mediated IFN signaling in breast cancer. J Immunol. 2019;202(10):3076–3086. doi:10.4049/jimmunol.1801152
   PubMed Web of Science ®Google Scholar
• Leon-Cabrera S, Vazquez-Sandoval A, Molina-Guzman E, et al. Deficiency in STAT1 signaling predisposes gut inflammation and prompts colorectal cancer development. Cancers (Basel). 2018;10:9. doi:10.3390/cancers10090341
   PubMed Web of Science ®Google Scholar
• Crncec I, Modak M, Gordziel C, et al. STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer. Mol Oncol. 2018;12(4):514–528. doi:10.1002/1878-0261.12178
   PubMed Web of Science ®Google Scholar
• Meissl K, Macho-Maschler S, Muller M, Strobl B. The good and the bad faces of STAT1 in solid tumours. Cytokine. 2017;89:12–20. doi:10.1016/j.cyto.2015.11.011
   PubMed Web of Science ®Google Scholar
• Schellerer VS, Langheinrich MC, Zver V, et al. Soluble intercellular adhesion molecule-1 is a prognostic marker in colorectal carcinoma. Int J Colorectal Dis. 2019;34(2):309–317. doi:10.1007/s00384-018-3198-0
   PubMed Web of Science ®Google Scholar
• Shimura T, Shibata M, Gonda K, et al. Clinical significance of soluble intercellular adhesion Molecule-1 and Interleukin-6 in patients with extrahepatic cholangiocarcinoma. J Invest Surg. 2018;31(6):475–482. doi:10.1080/08941939.2017.1358310
   PubMed Web of Science ®Google Scholar
• Figenschau SL, Knutsen E, Urbarova I, et al. ICAM1 expression is induced by proinflammatory cytokines and associated with TLS formation in aggressive breast cancer subtypes. Sci Rep. 2018;8(1):11720. doi:10.1038/s41598-018-29604-2
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang Y, Cao Y, Zhang X, Zhao H. Increased CCL19 expression is associated with progression in cervical cancer. Oncotarget. 2017;8(43):73817–73825. doi:10.18632/oncotarget.17982
   PubMedGoogle Scholar
• Tokunaga R, Naseem M, Lo JH, et al. B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev. 2019;73:10–19. doi:10.1016/j.ctrv.2018.12.001
   PubMed Web of Science ®Google Scholar
• Saxena V, Li L, Paluskievicz C, et al. Role of lymph node stroma and microenvironment in T cell tolerance. Immunol Rev. 2019;292(1):9–23. doi:10.1111/imr.12799
   PubMed Web of Science ®Google Scholar
• O’Connor T, Zhou X, Kosla J, et al. Age-related gliosis promotes central nervous system lymphoma through CCL19-mediated tumor cell retention. Cancer Cell. 2019;36(3):250–267 e259. doi:10.1016/j.ccell.2019.08.001
   PubMed Web of Science ®Google Scholar
• Matsuki E, Younes A. Lymphomagenesis in Hodgkin lymphoma. Semin Cancer Biol. 2015;34:14–21. doi:10.1016/j.semcancer.2015.02.002
   PubMed Web of Science ®Google Scholar
• Ren Z, Liang S, Yang J, et al. Coexpression of CXCR4 and MMP9 predicts lung metastasis and poor prognosis in resected osteosarcoma. Tumour Biol. 2016;37(4):5089–5096. doi:10.1007/s13277-015-4352-8
   PubMedGoogle Scholar
• Li Q, Chen B, Cai J, et al. Comparative analysis of matrix metalloproteinase family members reveals that MMP9 predicts survival and response to temozolomide in patients with primary glioblastoma. PLoS One. 2016;11(3):e0151815. doi:10.1371/journal.pone.0151815
   PubMed Web of Science ®Google Scholar
• Yang XZ, Cui SZ, Zeng LS, et al. Overexpression of Rab1B and MMP9 predicts poor survival and good response to chemotherapy in patients with colorectal cancer. Aging (Albany NY). 2017;9(3):914–931. doi:10.18632/aging.101200
   PubMedGoogle Scholar
• Wang Q, Yao J, Jin Q, et al. LAMP1 expression is associated with poor prognosis in breast cancer. Oncol Lett. 2017;14(4):4729–4735. doi:10.3892/ol.2017.6757
   PubMed Web of Science ®Google Scholar
• Dang Q, Zhou H, Qian J, et al. LAMP1 overexpression predicts for poor prognosis in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(11):749–754. doi:10.1016/j.clml.2018.07.288
   PubMed Web of Science ®Google Scholar
• Shao H, Ma L, Jin F, Zhou Y, Tao M, Teng Y. Immune inhibitory receptor LILRB2 is critical for the endometrial cancer progression. Biochem Biophys Res Commun. 2018;506(1):243–250. doi:10.1016/j.bbrc.2018.09.114
   PubMed Web of Science ®Google Scholar
• Gao A, Sun Y, Peng G. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy. Biochim Biophys Acta Rev Cancer. 2018;1869(2):278–285. doi:10.1016/j.bbcan.2018.04.001
   PubMed Web of Science ®Google Scholar
• Cai Z, Wang L, Han Y, et al. Immunoglobulinlike transcript 4 and human leukocyte antigenG interaction promotes the progression of human colorectal cancer. Int J Oncol. 2019;54(6):1943–1954. doi:10.3892/ijo.2019.4761
   PubMed Web of Science ®Google Scholar
• Chen HM, van der Touw W, Wang YS, et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest. 2018;128(12):5647–5662. doi:10.1172/JCI97570
   PubMed Web of Science ®Google Scholar
• Poh AR, Love CG, Masson F, et al. Inhibition of hematopoietic cell kinase activity suppresses myeloid cell-mediated colon cancer progression. Cancer Cell. 2017;31(4):563–575 e565. doi:10.1016/j.ccell.2017.03.006
   PubMed Web of Science ®Google Scholar
• Roversi FM, Pericole FV, Machado-Neto JA, et al. Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway. Biochim Biophys Acta Mol Basis Dis. 2017;1863(2):450–461. doi:10.1016/j.bbadis.2016.11.013
   PubMed Web of Science ®Google Scholar
• Roseweir AK, Powell A, Horstman SL, et al. Src family kinases, HCK and FGR, associate with local inflammation and tumour progression in colorectal cancer. Cell Signal. 2019;56:15–22. doi:10.1016/j.cellsig.2019.01.007
   PubMed Web of Science ®Google Scholar
• Mangogna A, Belmonte B, Agostinis C, et al. Prognostic implications of the complement protein C1q in gliomas. Front Immunol. 2019;10:2366. doi:10.3389/fimmu.2019.02366
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Y, Wu W, et al. Guanylate-binding protein 2 regulates Drp1-mediated mitochondrial fission to suppress breast cancer cell invasion. Cell Death Dis. 2018;9(11):1127. doi:10.1038/s41419-018-1133-5
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulos C, Vrugt B, Flury R, et al. Identification and validation of a biomarker signature in patients with resectable pancreatic cancer via genome-wide screening for functional genetic variants. JAMA Surg. 2019;154(6):e190484. doi:10.1001/jamasurg.2019.0484
   PubMed Web of Science ®Google Scholar
• Lin Z, Wang H, Zhang Y, et al. Development and validation of a prognostic nomogram to guide decision-making for high-grade digestive neuroendocrine neoplasms. Oncologist. 2019;25(4):e659–e667. doi:10.1634/theoncologist.2019-0566
   PubMed Web of Science ®Google Scholar
• Semenkovich TR, Yan Y, Subramanian M, et al. A clinical nomogram for predicting node-positive disease in esophageal cancer. Ann Surg. 2019;270(3):434–443. doi:10.1097/SLA.0000000000003466
   PubMed Web of Science ®Google Scholar